China NMPA Drug Inspection - Yichang Renfu Pharmaceutical - Simvastatin capsules
China NMPA drug inspection for Yichang Renfu Pharmaceutical published January 22, 2020. Drug: Simvastatin capsules. The Ningxia Drug Administration, operating under China's National Medical Products Administration, published an announce
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Yichang Renfu Pharmaceutical published January 22, 2020. Drug: Simvastatin capsules. The Ningxia Drug Administration, operating under China's National Medical Products Administration, published an announce
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Company
Yichang Renfu PharmaceuticalInspection Date
Unknown Date
Product Type
ID: 990356fe-d055-47f5-8ccb-e7c96bfe17b1
View on DashboardTransform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox